IDEXX Laboratories (NASDAQ:IDXX) EVP Sharon Underberg Sells 8,906 Shares of Company Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) EVP Sharon Underberg sold 8,906 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $688.59, for a total transaction of $6,132,582.54. Following the completion of the sale, the executive vice president owned 7,169 shares in the company, valued at $4,936,501.71. This represents a 55.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

IDEXX Laboratories Stock Down 4.0%

IDXX opened at $670.71 on Friday. The company has a fifty day moving average price of $544.13 and a 200-day moving average price of $573.40. The firm has a market capitalization of $52.84 billion, a P/E ratio of 45.23 and a beta of 1.55. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.19 billion. During the same quarter last year, the business posted $3.22 earnings per share. The firm’s revenue was up 9.9% compared to the same quarter last year. Equities research analysts expect that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current fiscal year.

More IDEXX Laboratories News

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: Morgan Stanley raised its price target on IDEXX, a potentially supportive analyst signal; the report provided here does not specify the new target. Morgan Stanley price target report
• Positive Sentiment: IDEXX’s Q3 results were described as best-in-class. The company reported EPS of $3.96, above the $3.71 consensus, and revenue of $1.21 billion, ahead of estimates and up 9.9% year over year. IDEXX Q3 results analysis
• Negative Sentiment: A Seeking Alpha article downgraded the stock, arguing that despite IDEXX’s strong business, its shares are too expensive. Valuation concerns may limit investor appetite. IDEXX valuation downgrade
• Negative Sentiment: Four directors and executives reported selling a combined 39,225 shares on November 4, worth about $27.4 million. Each reduced their reported holdings, a potential near-term sentiment headwind, though insider sales alone do not establish the reason for selling. Read More., Read More., Read More., Read More..

Analyst Ratings Changes

Several research analysts have recently commented on IDXX shares. JPMorgan Chase & Co. cut their price objective on IDEXX Laboratories from $775.00 to $750.00 and set an “overweight” rating for the company in a report on Friday, October 16th. BTIG Research dropped coverage on shares of IDEXX Laboratories in a report on Friday, October 30th. They set a “buy” rating on the stock. Jefferies Financial Group decreased their price target on IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a research note on Tuesday, October 20th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, KeyCorp initiated coverage on IDEXX Laboratories in a report on Monday, October 12th. They set a “sector weight” rating for the company. Seven investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $719.55.

Institutional Investors Weigh In On IDEXX Laboratories

Institutional investors have recently made changes to their positions in the company. Arlington Trust Co LLC increased its holdings in IDEXX Laboratories by 46.3% in the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock worth $32,000 after buying an additional 19 shares in the last quarter. Bell Investment Advisors Inc raised its position in IDEXX Laboratories by 45.5% in the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock worth $33,000 after buying an additional 20 shares during the last quarter. Annis Gardner Whiting Capital Advisors LLC lifted its stake in IDEXX Laboratories by 21.4% during the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company’s stock valued at $67,000 after acquiring an additional 21 shares during the period. Arlington Capital Management Inc. lifted its stake in IDEXX Laboratories by 4.8% during the 1st quarter. Arlington Capital Management Inc. now owns 479 shares of the company’s stock valued at $269,000 after acquiring an additional 22 shares during the period. Finally, Valeo Financial Advisors LLC lifted its stake in IDEXX Laboratories by 6.4% during the 2nd quarter. Valeo Financial Advisors LLC now owns 383 shares of the company’s stock valued at $202,000 after acquiring an additional 23 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.